Correlation between parathyroid hormone, bone alkaline phosphatase and N-telopeptide of type 1 collagen in diabetic and non-diabetic haemodialysis patients

Corresponding Author

NOBUNORI TAKAHASHI

Department of Orthopaedic Surgery, Nagoya University School of Medicine, and

Dr Nobunori Takahashi, Department of Orthopaedic Surgery, Nagoya University, School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya 466-8550, Japan. Email: [email protected]Search for more papers by this author

TOSHIHISA KOJIMA,

TOSHIHISA KOJIMA

Department of Orthopaedic Surgery, Nagoya University School of Medicine, and

Search for more papers by this author

HIROSHI OGAWA,

HIROSHI OGAWA

Department of Internal Medicine, Shinseikai-Daiichi Hospital, Nagoya, Japan

Search for more papers by this author

NAOKI ISHIGURO,

NAOKI ISHIGURO

Department of Orthopaedic Surgery, Nagoya University School of Medicine, and

Search for more papers by this author

NOBUNORI TAKAHASHI,

Corresponding Author

NOBUNORI TAKAHASHI

Department of Orthopaedic Surgery, Nagoya University School of Medicine, and

TOSHIHISA KOJIMA,

TOSHIHISA KOJIMA

Department of Orthopaedic Surgery, Nagoya University School of Medicine, and

Search for more papers by this author

HIROSHI OGAWA,

HIROSHI OGAWA

Department of Internal Medicine, Shinseikai-Daiichi Hospital, Nagoya, Japan

Search for more papers by this author

NAOKI ISHIGURO,

NAOKI ISHIGURO

Department of Orthopaedic Surgery, Nagoya University School of Medicine, and

Search for more papers by this author

First published: 12 July 2007

https://doi.org/10.1111/j.1440-1797.2007.00829.x

Citations: 5

Share a link

Email
Wechat
Bluesky

SUMMARY:

Background: Haemodialysis (HD) patients with diabetes mellitus often have renal osteodystrophy (ROD) characterized by reduced bone turnover, but little is known about the correlation between bone formation and bone resorption in this population.

Methods: The authors measured serum parathyroid hormone (PTH), bone alkaline phosphatase (BAP), N-telopeptides of type 1 collagen (NTx) and fasting glucose in 48 patients with diabetic nephropathy (DN) and 80 patients with glomerulonephritis (non-DN) who had received ≤10 years of regular HD. Spearman's correlation coefficients (r) were derived.

Results: In the whole patients, the DN group had a lower PTH and NTx level than the non-DN group. Serum PTH was not correlated with NTx in the DN group, whereas all three markers were correlated with each other in the non-DN group. Subdividing the DN patients according to HD duration revealed remarkable differences in the correlation between BAP and NTx: in patients receiving ≥5 years HD (r = 0.568) this correlation was similar to that in the non-DN group (r = 0.653), whereas there was no significant correlation in those receiving <5 years HD. Patients receiving ≥5 years HD had a comparable glucose level (111.1 ± 19.2 mg/dL) to the non-DN group, whereas those receiving <5 years had a higher level (196.1 ± 53.1 mg/dL).

Conclusion: Differences in the interaction between bone cells between DN and non-DN patients are one potential cause of lower bone turnover in the former group. Research of this correlation is needed to increase understanding of the complexities of bone metabolism in DN patients.

REFERENCES

1 Inaba M, Okuno S, Nagasue K et al. Impaired secretion of parathyroid hormone is coherent to diabetic hemodialyzed patients. Am. J. Kidney Dis. 2001; 38: S139–42.
Google Scholar
2 Pei Y, Hercz G, Greenwood C et al. Renal osteodystrophy in diabetic patients. Kidney Int. 1993; 44: 159–64.
Google Scholar
3 Aubia J, Bosch J, Lloveras J et al. Low incidence of hyperparathyroidism in diabetic renal failure. Proc. Eur. Dial. Transplant Assoc. Eur. Ren. Assoc. 1985; 21: 902–8.
Google Scholar
4 Levy JR, Murray E, Manolagas S, Olefsky JM. Demonstration of insulin receptors and modulation of alkaline phosphatase activity by insulin in rat osteoblastic cells. Endocrinology 1986; 119: 1786–92.
Google Scholar
5 Coen G, Ballanti P, Bonucci E et al. Bone markers in the diagnosis of low turnover osteodystrophy in haemodialysis patients. Nephrol. Dial. Transplant. 1998; 13: 2294–302.
Google Scholar
6 Franke S, Lehmann G, Abendroth K, Hein G, Stein G. PICP as bone formation and NTx as bone resorption marker in patients with chronic renal failure. Eur. J. Med. Res. 1998; 3: 81–8.
Google Scholar
7 Ueda M, Inaba M, Okuno S et al. Clinical usefulness of the serum N-terminal propeptide of type I collagen as a marker of bone formation in hemodialysis patients. Am. J. Kidney Dis. 2002; 4: 802–9.
Google Scholar
8 Urena P, Hruby M, Ferreira A, Ang KS, De Vernejoul MC. Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients. J. Am. Soc. Nephrol. 1996; 7: 506–12.
Google Scholar
9 Alvarez L, Torregrosa JV, Peris P et al. Effect of hemodialysis and renal failure on serum biochemical markers of bone turnover. J. Bone Miner Metab. 2004; 22: 254–9.
Google Scholar
10 Clemens JD, Herrick MV, Singer FR, Eyre DR. Evidence that serum NTx (collagen-type I N-telopeptides) can act as an immunochemical marker of bone resorption. Clin. Chem. 1997; 43: 2058–63.
10.1093/clinchem/43.11.2058
CAS PubMed Web of Science® Google Scholar
11 Montagnani A, Gonnelli S, Cepollaro C et al. A new serum assay to measure N-terminal fragment of telopeptide of type I collagen in patients with renal osteodystrophy. Eur. J. Intern. Med. 2003; 14: 172–7.
10.1016/S0953-6205(03)00034-7
CAS PubMed Google Scholar
12 Inaba M, Nishizawa K, Mita K et al. Poor glycemic control impairs the response of biochemical parameters of bone formation and resorption to exogenous 1,25-dihydroxyvitamin D₃ in patients with type 2 diabetes. Osteoporos. Int. 1999; 9: 525–31.
10.1007/s001980050180
CAS PubMed Web of Science® Google Scholar
13 Indridason OS, Pieper CF, Quarles LD. Predictors of short-term changes in serum intact parathyroid hormone levels in hemodialysis patients: Role of phosphorus, calcium, and gender. J. Clin. Endocrinol. Metab. 1998; 83: 3860–66.
10.1210/jc.83.11.3860
CAS PubMed Web of Science® Google Scholar
14 Malluche HH. Aluminium and bone disease in chronic renal failure. Nephrol. Dial Transplant. 2002; 17 (Suppl 2): 21–4.
10.1093/ndt/17.suppl_2.21
CAS PubMed Web of Science® Google Scholar
15 WHO Expert Committee. Second Report on Diabetes Mellitus. Technical report series 646. Geneva: WHO, 2003; 180–89.
Google Scholar
16 McSheehy PM, Chambers TJ. Osteoblastic cells mediate osteoclastic responsiveness to parathyroid hormone. Endocrinology 1986; 118: 824–8.
10.1210/endo-118-2-824
CAS PubMed Web of Science® Google Scholar
17 Athanasou NA. Current concepts review – Cellular biology of bone-resorbing cells. . J. Bone Joint Surg. Am. 1996; 78: 1096–112.
10.2106/00004623-199607000-00016
CAS PubMed Web of Science® Google Scholar
18 Mizumoto D, Watanabe Y, Fukuzawa Y, Yuzawa Y, Yamazaki C. Identification of risk factors on secondary hyperparathyroidism undergoing long-term haemodialysis with vitamin D3. Nephrol. Dial. Transplant. 1994; 9: 1751–8.
PubMed Web of Science® Google Scholar
19 Inaba M, Nishizawa Y, Shioi A, Morii H. Importance of sustained high glucose condition in the development of diabetic osteopenia: Possible involvement of the polyol pathway. Osteoporos. Int 1997; 7 (Suppl 1): S209–12.
10.1007/BF03194374
CAS PubMed Web of Science® Google Scholar
20 Kanatani M, Sugimoto T, Kano J, Kanazawa M, Chihara K. Effect of high phosphate concentration on osteoclast differentiation as well as bone-resorbing activity. J. Cell Physiol. 2003; 196: 180–89.
10.1002/jcp.10270
CAS PubMed Web of Science® Google Scholar
21 Ueda M, Inaba M, Okuno S et al. Serum BAP as the clinically useful marker for predicting BMD reduction in diabetic hemodialysis patients with low PTH. Life Sci. 2005; 77: 1130–39.
10.1016/j.lfs.2005.02.007
CAS PubMed Web of Science® Google Scholar
22 Coen G, Ballanti P, Baducci A et al. Serum osteoprotegerin and renal osteodystrophy. Nephrol. Dial. Transplant. 2002; 17: 233–8.
10.1093/ndt/17.2.233
CAS PubMed Web of Science® Google Scholar
23 Endres DB, Villanueva R, Sharp CF et al. Immunochemiluminometric and immunoradiometric determinations of intact and total immunoreactive parathyrin: Performance in the differential diagnosis of hypercalcemia and hypoparathyroidism. Clin. Chem. 1991; 37: 162–8.
10.1093/clinchem/37.2.162
CAS PubMed Google Scholar
24 Yumita S, Suzuki M, Akiba T et al. Levels of serum 1,25 (OH) 2D in patients with pre-dialysis chronic renal failure. Tohoku J. Exp. Med. 1996; 180: 45–56.
10.1620/tjem.180.45
CAS PubMed Web of Science® Google Scholar
25 Mori S, Harada S, Okazaki R et al. Hypomagnesemia with increased metabolism of parathyroid hormone and reduced responsiveness to calcitropic hormones. Intern. Med. 1992; 31: 820–24.
10.2169/internalmedicine.31.820
CAS PubMed Web of Science® Google Scholar
26 Stock JL, Coderre JA, Posillico JT. Effects of estrogen on mineral metabolism in postmenopausal women as evaluated by multiple assays measuring parathyrin bioactivity. Clin. Chem. 1989; 35: 18–22.
10.1093/clinchem/35.1.18
CAS PubMed Web of Science® Google Scholar
27 Ansari A, Thomas S, Goldsmith D. Assessing glycemic control in patients with diabetes and end-stage renal failure. Am. J. Kidney Dis. 2003; 41: 523–31.
10.1053/ajkd.2003.50114
PubMed Web of Science® Google Scholar

Citing Literature

Volume12, Issue6

December 2007

Pages 539-545

Correlation between parathyroid hormone, bone alkaline phosphatase and N-telopeptide of type 1 collagen in diabetic and non-diabetic haemodialysis patients

SUMMARY:

REFERENCES

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Correlation between parathyroid hormone, bone alkaline phosphatase and N-telopeptide of type 1 collagen in diabetic and non-diabetic haemodialysis patients

SUMMARY:

REFERENCES

Citing Literature

References

Related

Information